Study on the Safe Dosage and Therapeutic Effect of the Drug YY2201 Tablets on Patients With Advanced Cancer

This is a multicenter, open-label, dose-escalation phase I study. participants will receive one single target dose of YY2201 on Cycle 0 Day 1 (C0D1) to observe safety and collect PK blood samples up to 48 h post-dose. On the third day after the first dose (Cycle 1 Day 1, C1D1), subjects will start to receive multiple doses of YY2201 orally twice daily (approximately 12 h interval) for 3 days followed by 4 days off in a 21-days treatment cycle.